Compare SWZ & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWZ | CRDF |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.5M | 67.1M |
| IPO Year | N/A | 2012 |
| Metric | SWZ | CRDF |
|---|---|---|
| Price | $5.85 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.28 |
| AVG Volume (30 Days) | 21.9K | ★ 364.0K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $5.68 | $0.72 |
| 52 Week High | $6.31 | $3.31 |
| Indicator | SWZ | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 30.76 |
| Support Level | $5.74 | N/A |
| Resistance Level | $5.99 | $1.13 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 50.28 | 5.60 |
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. It actively manages investment solutions spanning public and private markets, wealth management, and Solutions.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.